Wave Life Sciences’ obesity readouts pushed the company’s shares sharply lower, as investors digested data suggesting limited additional benefit from higher dosing of its INHBE-targeted program. The result was framed as delivering little incremental efficacy beyond what lower doses can achieve, reinforcing the uncertainty around the dose-response relationship. The move came shortly after broader coverage of Wave’s obesity data and highlights how dose-finding and biomarker-to-efficacy linkage can quickly change capital markets’ expectations for metabolic programs. For companies managing late-stage obesity development, the episode serves as a reminder that even incremental clinical differentiation may be needed to protect valuation when biology targets are crowded and competitive.